Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. - Wikidata - wikimedia - TriplyDB

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.

http://www.wikidata.org/entity/Q35672242

about

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes.Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.Early Increases in Bile Acids Post Roux-en-Y Gastric Bypass Are Driven by Insulin-Sensitizing, Secondary Bile Acids.An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.Ursodeoxycholic acid: effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.The crosstalk between gut microbiota and obesity and related metabolic disorders.New therapeutic concepts in bile acid transport and signaling for management of cholestasis.Bile acids and bariatric surgery.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.Repression of intestinal transporters and FXR-FGF15 signaling explains bile acids dysregulation in experimental colitis-associated colon cancer.Balancing Herbal Medicine and Functional Food for Prevention and Treatment of Cardiometabolic Diseases through Modulating Gut Microbiota.Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans.Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans.Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.Recent advances in understanding bile acid homeostasis.Reciprocal interactions between bile acids and gut microbiota in human liver diseases.Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.Comparative Effects of Bile Diversion and Duodenal-Jejunal Bypass on Glucose and Lipid Metabolism in Male Diabetic Rats.Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study.Bile acid metabolites in early pregnancy and risk of gestational diabetes in Chinese women: A nested case-control study Bile acid metabolism and signaling in liver disease and therapy Implication of gut microbiota metabolites in cardiovascular and metabolic diseases

P2860

Q34540703-6967C26C-82F3-4F1F-97D7-D5367AE057C7 Q36004096-40A67AFE-6A68-4185-B6CF-4EF9004AF462 Q36023779-628435C1-C55A-4BE3-B9C6-0E38B87F832F Q36060415-718F6E41-0B6C-48A1-AB73-59168ED60CCA Q36136449-DC958741-4131-4DC0-AAA4-20F48AA1907C Q36216779-FB9B9D4C-8CCA-4A27-956D-A54C1DCD294E Q36379436-36709145-194A-43C2-93F2-9ECF903482A3 Q37024454-5EC7AB0B-1A2E-4AEF-84F5-92CFDDCE5C8C Q37538343-61B07925-2AD1-4F53-9742-CBD4FE95C06A Q38602520-2631D32C-A948-48C5-A4E2-BD7C0C9DED08 Q38752520-6E8C4830-F7F1-4853-8160-289F00044A51 Q38837418-812B14D5-29BD-449B-94CA-567B3C7CBCC0 Q39044702-19997A4E-EA23-4ACE-93B2-307FFFF6A332 Q39228891-0E3DB8CD-4772-4ACD-A5A7-16E2F3E1AA9B Q39262148-4BB2E22C-28F9-4B9E-9B0B-CDA7E19F7091 Q41382617-27AB1E5C-23C3-418C-8D32-593A4C0B0178 Q42362727-3CF11C5D-8E04-4729-A1F7-411B2E35369C Q45849451-EE754F56-AD7B-4A2A-885A-F866BF81DCFE Q46488398-0247752D-8F8F-491B-98F8-558BC95E5643 Q46561979-62E5EC1B-D50C-4B16-AC79-BB3285A38DE5 Q47145401-5D2D16F7-8562-4935-9706-1D4FCC2ACE69 Q47162245-4B436E53-5F15-452B-9CD1-8F2C8AB74290 Q47389652-72CB74DD-F75D-408F-AEDD-106F89381F72 Q51265948-3FF72A92-6D6C-4C5A-A43E-CCDFCD157CA9 Q51295574-67B93AD9-606C-4E84-AC0D-0B3106AC9180 Q51731208-2AEED104-D7B1-456C-A3EC-CA8BADB2D717 Q57109538-E9E15680-3A17-4D54-8862-CDB02C645AF6 Q57128767-88969C0B-DC93-4258-BA12-17E79CE27B8C Q58787534-73A28DF7-BC1D-4DB8-9605-8DA658232CD8

P2860

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.

http://www.wikidata.org/entity/Q35672242

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Ursodeoxycholic acid exerts fa ...... metabolism in morbid obesity.

@ast

Ursodeoxycholic acid exerts fa ...... metabolism in morbid obesity.

@en

type

label

Ursodeoxycholic acid exerts fa ...... metabolism in morbid obesity.

@ast

Ursodeoxycholic acid exerts fa ...... metabolism in morbid obesity.

@en

prefLabel

Ursodeoxycholic acid exerts fa ...... metabolism in morbid obesity.

@ast

Ursodeoxycholic acid exerts fa ...... metabolism in morbid obesity.

@en

P1433

Q35672242-8D5CBCC4-1F4B-4678-8630-38F1861561C3

P1476

Q35672242-1F44BCA7-7642-4942-AF93-3811A195D649

P2093

Q35672242-102325EA-BDA7-41A6-AB03-57BD5C67A8E9

Q35672242-17FB9B08-4D5D-4650-BCC6-1E0610C2058F

Q35672242-3EA9C0C5-8A41-488F-95BB-96A5458C1048

Q35672242-4596C08B-5D09-4E12-A815-C728A545AD57

Q35672242-66693BD8-764B-468E-8EEB-E0C0F36E5167

Q35672242-6A9634E8-608C-4753-9360-BD34173669D3

Q35672242-6EC8FC3E-478E-4E71-9912-E16CD98B72F0

Q35672242-9F2CAF78-9DF2-4994-BA33-D69F59CB1ED0

Q35672242-A5269B34-EDA0-4B0D-86BA-C16F66C385D3

Q35672242-F228CD63-8155-42A7-BDF4-8D6357BF09D9

P2860

Q35672242-044026D4-1ABD-4225-AA0C-7AF338989999

Q35672242-0EEC60BD-0788-4229-8DB6-473BCFBEE2AE

Q35672242-1265BFEE-5E6B-4769-B29B-D22198AC4859

Q35672242-2389882A-0879-4A5B-9A85-8F097D7C8BAD

Q35672242-23DFC1D0-1C8D-4D98-BC40-5F1444F19946

Q35672242-244E2014-D617-41F9-92F9-A0C881CB1CFC

Q35672242-2D8B242A-3EA0-448A-A5BF-12D0E032070B

Q35672242-38EDF967-667A-430F-A58E-AC5C3D5B7AD7

Q35672242-3E969C73-C44A-44F1-B048-3402AD621293

Q35672242-3F3F0F1E-AFC7-429A-B665-F9246BDD8F2B

P304

Q35672242-5FF0B81E-A38F-458D-BA93-66FFF961E66B

P31

Q35672242-0EBB8CF6-93BF-4F6C-86F3-4EE083EEC7C2

P356

Q35672242-E428D9B2-F481-4715-B1E3-D7548169DFD2

P433

Q35672242-CACA9E50-02B8-44D2-8764-EC59B202A031

P478

Q35672242-84C825C2-DE60-4F2B-ADFC-2E8A138D4738

P50

Q35672242-7E1BBD26-5D5E-46CC-96F7-808D9D43638A

Q35672242-98B22D64-3C33-4617-A1DF-624D7108F8A6

P577

Q35672242-B3636D30-D2DA-42BC-98F4-75DCCE495C3C

P5875

Q35672242-1254ABDB-56B2-4DC9-9582-9E8B8B0DDA8B

P698

Q35672242-FC28AD1A-8E45-47A4-AFF5-9E78264A9C78

P921

Q35672242-D1CF5A36-9263-4D39-A884-24F4E6DEB31A

P932

Q35672242-6543E4FF-18AF-4262-9AB3-A16423728D0A

P356

J.JHEP.2014.12.034

P1433

Journal of Hepatology

P1476

Ursodeoxycholic acid exerts fa ...... metabolism in morbid obesity.

@en

P2093

Anders Thorell

http://www.w3.org/2001/XMLSchema#string

Carolin Lackner

http://www.w3.org/2001/XMLSchema#string

Curt Einarsson

http://www.w3.org/2001/XMLSchema#string

Guenter Fauler

http://www.w3.org/2001/XMLSchema#string

Hanns-Ulrich Marschall

http://www.w3.org/2001/XMLSchema#string

Harald Koefeler

http://www.w3.org/2001/XMLSchema#string

Michael Trauner

http://www.w3.org/2001/XMLSchema#string

Michaela Mueller

http://www.w3.org/2001/XMLSchema#string

Tatjana Stojakovic

http://www.w3.org/2001/XMLSchema#string

Thierry Claudel

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a nuclear receptor for bile acids

Bile acids: natural ligands for an orphan nuclear receptor

Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors

The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion

Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

LXRS and FXR: the yin and yang of cholesterol and fat metabolism

FATP1 is an insulin-sensitive fatty acid transporter involved in diet-induced obesity.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes

P304

1398-1404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2014.12.034

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271329390

http://www.w3.org/2001/XMLSchema#string

P698

25617503

http://www.w3.org/2001/XMLSchema#string

P921

P932

4451470

http://www.w3.org/2001/XMLSchema#string